Effect of Magnesium on Remifentanil Induced Cough

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-03

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of this study is that Magnesium sulfate pretreatment (50mg/kg) will reduce the incidence of cough and chest wall rigidity caused by remifentanil administration.

The purpose of this study was to investigate the effect of magnesium sulfate administered before induction of anesthesia on thoracic stiffness and cough response caused by opioid analgesics administered for general anesthesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intubating Condition After Magnesium Pre-treatment

NCT01153256

Easy of Laryngoscopy Manipulation Vocal Cord Position or Movement Patient Reaction to Intubation and Cuff Inflation +2 more

COMPLETED NA

Smooth Extubation With Magnesium Sulphate for General Anesthesia With Endotracheal Intubation

NCT04617652

Smooth Extubation

COMPLETED PHASE4

Effect of Remifentanil on Cough During Emergence From General Anesthesia : Trial to Compare Between Sevoflurane Anesthesia and Propofol Anesthesia

NCT01240109

Elective Thyroidectomy

COMPLETED PHASE4

Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia

NCT01026129

Cough Anesthesia Extubation

COMPLETED NA

Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia

NCT01489072

Cough Anesthesia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

magnesium group

magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

Group Type EXPERIMENTAL

Magnesium sulfate

Intervention Type DRUG

magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

control group

normal saline 100ml (loading for 10 minutes), 15mg/kg/hr (continuous infusion)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium sulfate

magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

Intervention Type DRUG

Placebo

normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 20-75 years of age who are undergoing surgery under general anesthesia using a laryngeal mask and who have consented to participate in this study among American Society of Anesthesiologists body grade 1 or 2

Exclusion Criteria

* When coughing may occur due to an underlying disease (upper respiratory infection, rhinitis, post nasal drip, asthma, chronic obstructive pulmonary disease, pneumonia, bronchitis, current smokers, etc.)
* If you have kidney disease that can affect magnesium metabolism (glomerular filtration rate less than 60)
* If you are taking opioid analgesics or magnesium for other reasons
* Patients with hypermagnesemia
* Patients with atrioventricular block (stages I-III) or other cardiac conduction disorders
* Pregnant or lactating women
* Patients with myasthenia gravis
* Patients taking drugs that are contraindicated or interact with magnesium (barbitalates, aminoglycoside antibiotics, isoniazid, chlorpromazine, digoxin)
* In case of hypersensitivity to magnesium
* Patients with a history of hypersensitivity to propofol and any of its components
* Patients with a history of hypersensitivity to remifentanil and other fentanyl analogues

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No